Ismail O. Kara

Adana, 01330, Turkey

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 34 publications

Quantitative Immunohistochemical Landscapes and Chemoimmunotherapy Outcomes of ASCL1, NEUROD1, POU2F3, and YAP1 in Pure Small-Cell Lung Cancer: A Pilot Study.

Quantitative Immunohistochemical Landscapes and Chemoimmunotherapy Outcomes of ASCL1, NEUROD1, POU2F3, and YAP1 in Pure Small-Cell Lung Cancer: A Pilot Study.

Journal: Journal of clinical medicine

Published: July 19, 2026

Clinicopathological Features, Tumor Localization and Treatment Outcomes in Paraganglioma: A Single-Center Medical Oncology Cohort.

Clinicopathological Features, Tumor Localization and Treatment Outcomes in Paraganglioma: A Single-Center Medical Oncology Cohort.

Journal: Diagnostics (Basel, Switzerland)

Published: June 29, 2026

Real-World Outcomes and Prognostic Factors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Sorafenib: A Multicenter Study.

Real-World Outcomes and Prognostic Factors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Sorafenib: A Multicenter Study.

Journal: Journal of clinical medicine

Published: May 28, 2026

Immune-related adverse events as predictors of pathological complete response in early-stage triple-negative breast cancer treated with pembrolizumab.

Immune-related adverse events as predictors of pathological complete response in early-stage triple-negative breast cancer treated with pembrolizumab.

Journal: Immunotherapy

Published: April 21, 2026

Feasibility and Concordance of a Large Language Model (ChatGPT-5) as a Clinical Decision Support Tool in Gynecologic Oncology Tumor Boards: A Blinded, Multi-Observer Study.

Feasibility and Concordance of a Large Language Model (ChatGPT-5) as a Clinical Decision Support Tool in Gynecologic Oncology Tumor Boards: A Blinded, Multi-Observer Study.

Journal: Journal of clinical medicine

Published: April 15, 2026

Preoperative Lactate Dehydrogenase-to-Albumin Ratio as a Tumor-Host Biomarker of Early Recurrence and Survival in Resected Pulmonary Neuroendocrine Carcinomas: A Multicenter Observational Cohort Study.

Preoperative Lactate Dehydrogenase-to-Albumin Ratio as a Tumor-Host Biomarker of Early Recurrence and Survival in Resected Pulmonary Neuroendocrine Carcinomas: A Multicenter Observational Cohort Study.

Journal: Medicina (Kaunas, Lithuania)

Published: April 14, 2026

Dose-Adjusted EPOCH-R in Aggressive B-Cell Lymphomas: Efficacy, Molecular Prognostic Factors, and Real-World Outcomes from a Multicenter Turkish Cohort-A Turkish Oncology Group (TOG) Study.

Dose-Adjusted EPOCH-R in Aggressive B-Cell Lymphomas: Efficacy, Molecular Prognostic Factors, and Real-World Outcomes from a Multicenter Turkish Cohort-A Turkish Oncology Group (TOG) Study.

Journal: Medicina (Kaunas, Lithuania)

Published: April 10, 2026

Impact of Anatomical Localization on Systemic Inflammatory Markers and Immune Checkpoint CD47 in Desmoid Tumors.

Impact of Anatomical Localization on Systemic Inflammatory Markers and Immune Checkpoint CD47 in Desmoid Tumors.

Journal: Journal of clinical medicine

Published: April 02, 2026

Resectable Stage Early-Onset Biliary Tract Cancer: Survival and Prognostic Scoring (EOB-RS and EOB-OS) in Turkish Patients (TOG/GI-SAFRADJU-2502-EO).

Resectable Stage Early-Onset Biliary Tract Cancer: Survival and Prognostic Scoring (EOB-RS and EOB-OS) in Turkish Patients (TOG/GI-SAFRADJU-2502-EO).

Journal: JCO global oncology

Published: March 26, 2026

Tyrosine Kinase Inhibitor Therapy in Metastatic Medullary Thyroid Carcinoma: Real-World Data from Turkish Oncology Group.

Tyrosine Kinase Inhibitor Therapy in Metastatic Medullary Thyroid Carcinoma: Real-World Data from Turkish Oncology Group.

Journal: Journal of clinical medicine

Published: March 01, 2026

Comparison of flat-dose versus weight-based dose nivolumab treatment in NSCLC patients.

Comparison of flat-dose versus weight-based dose nivolumab treatment in NSCLC patients.

Journal: Scientific reports

Published: February 20, 2026

Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers: National, Comparative, Observational Study (TOG/GI-SAFRADJU-2501).

Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers: National, Comparative, Observational Study (TOG/GI-SAFRADJU-2501).

Journal: International journal of cancer

Published: February 09, 2026

Showing 1-12 of 34

Last Updated: 09/26/2026